Insilico Medicine and ChemDiv form a strategic drug discovery service alliance

San

Diego (CA) - Insilico Medicine and ChemDiv, Inc. launched a new strategic

collaboration to provide certain pharmaceutical and biotechnology companies

with end-to-end drug discovery solutions. This collaboration combines the most

advanced artificial intelligence (AI) techniques with a

premium integrated drug discovery shared risk platform. The combination of complementary capabilities introduces

a new value for companies working in the field, giving them a powerful tool for

quick, cost-effective therapeutic product development.

“We’re

pleased to partner with ChemDiv, the leading discovery contract research

organization, which built a massive repository of small molecules,” said Alex

Zhavoronkov, PhD., CEO of Insilico Medicine. “ChemDiv has had a number of

highly successful collaborations with pharmaceutical companies in multiple

therapeutic areas, moving their discoveries from the

unique chemistry idea into the clinic. Together we willimprove the novelty, quality and

efficiency of preclinical drug discovery and bring our technology and

experience to other biotech and pharma partners.”

Sergey

Bugrov, Executive Director of ChemDiv said: “With Insilico Medicine’s AI

technology, previously intractable targets could  become viable therapeutic opportunities and

the time for preclinical drug discovery could dramatically shorten. Our joint goal is to generate new leads against identified and

predicted novel targets. It

allows us to continuously deliver great service to our partners and help them

develop effective treatments for unmet medical needs.”

The

commercial terms will include technology access, success focused milestone and

royalties.

About

ChemDiv

ChemDiv is a recognized global leader in drug

discovery solutions. Over the past 29 years ChemDiv has delivered hundreds of

leads, drug candidates and new drugs in the area of CNS, oncology, virology,

inflammation, cardiometabolic and immunology, to pharma, biotech and academic

partners around the globe. [www.chemdiv.com]

About

Insilico Medicine

Insilico Medicine is an artificial intelligence company headquartered in Hong Kong, with offices in six countries and regions. The Company was the first to apply the generative adversarial networks (GANs) and reinforcement learning (RL) to generate new molecular structures with the specified parameters in 2015. In addition to collaborating with large pharmaceutical companies, Insilico Medicine is also pursuing internal drug discovery programs in different disease areas and anti-aging fields. Recently, Insilico Medicine published some of the resuts in Nature Biotechnology, and secured $37 million in series B funding. Website http://insilico.com/

Media Contacts

For further information, images or interviews, please contact:

Insilico Medicine:

Klug Gehilfe, ai@pharma.ai

ChemDiv Inc.: Ron Demuth, rdemuth@chemdiv.com